PCSK9 inhibitors apart from obvious ability to reduce LDL can inhibit the progression of atherosclerosis by modifying the profile of pro-inflammatory cytokines, adhesion factors, and regulatory proteins. The gene discussed is PCSK9; the disease is atherosclerosis.